Sandbox MEN 2 epi: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC_ {{Multiple endocrine neoplasia type 2}} {{CMG}}; {{AE}} {{Ammu}} ==Overview== ==Prevalence== **Worldwide, the prevalence of (insert disease state here) is ___...")
 
No edit summary
 
(One intermediate revision by the same user not shown)
Line 6: Line 6:


==Overview==
==Overview==
==Prevalence==
==Prevalence==
**Worldwide, the [[prevalence]] of (insert disease state here) is _____ per 100,000 persons.
**Worldwide, the [[prevalence]] of multiple endocrine neoplasia type 2 is 2.5 per 100,000 persons in 2010.
**In developed countries, the [[prevalence]] of (insert disease state here) ranges from a low of _____ per 100,000 persons  to a high of _____ per 100,000 persons with an average prevalence of _____ per 100,000 persons.
** In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person.
**In developed countries, the [[prevalence]] of (insert disease state here) is _____ per 100,000 persons.
** MEN2 has been reported in approximately 500 to 1000 families worldwide.<ref name=Orphanet>{{cite web | title = Orphanet| url =http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653 }}</ref>
**In developing countries/ Africa, the [[prevalence]] of (insert disease state here) ranges from a low of _____ per 100,000 persons  to a high of _____ per 100,000 persons with an average prevalence of _____ per 100,000 persons.
** 70-80% of all multiple endocrine neoplasia type 2 cases are MEN type 2A.  
**In developing countries/ Africa, the [[prevalence]] of (insert disease state here) is _____ per 100,000 persons.


==Incidence==
==Incidence==
**Worldwide, the [[incidence]] of (insert disease state here) ranges from a low of _____ per 100,000 persons  to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
**Worldwide, the [[incidence]] of (insert disease state here) is _____ per 100,000 persons.
**In developed countries, the [[incidence]] of (insert disease state here) ranges from a low of _____ per 100,000 persons  to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
**In developed countries, the [[incidence]] of (insert disease state here) is _____ per 100,000 persons.
**In developed countries, the [[incidence]] of (insert disease state here) is _____ per 100,000 persons.
**In developing countries/ Africa, the [[incidence]] of (insert disease state here) ranges from a low of _____ per 100,000 persons  to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
**In developing countries/ Africa, the [[incidence]] of (insert disease state here) is _____ per 100,000 persons.


==Age==
==Age==
*The [[prevalence]] of (insert disease state here) increases/decreases with age.
* It can be found in all ages.
* MEN 2B manifest in early infancy while MEN 2A and familial medullary thyroid carcinoma is found in adulthood.


==Gender==
==Gender==
* The prevalence and incidence of (insert disease state here) does not vary by gender.
* The prevalence and incidence of multiple endocrine neoplasia type 2 does not vary by gender.
* Men and women are affected equally by (insert disease name here).
* (Insert disease state here) is more prevalent in men  women.
* The [[prevalence]] of (insert disease state here) among men is ____ per 100,000, while it is _____ per 100,000 among women.
* The [[incidence]] of (insert disease state here) among men is ____ per 100,000, while it is _____ per 100,000 among women.


==Race==
==Race==
* The prevalence of (insert disease state here) does not vary by race.
* The prevalence of multiple endocrine neoplasia type 2 does not vary by race.
* (Insert disease state here) is more prevalent in the ____race and ____ races.


==Developed Countries==
==Developed Countries==
* Incidence, prevalence, and geographical distribution or areas of interest can be mentioned, as well as the impact the disease has on society.
* In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person..
 
==Developing Countries==
* Incidence, prevalence, and geographical distribution or areas of interest can be mentioned, as well as the impact the disease has on society.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 15:04, 22 September 2015

__NOTOC_

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Sandbox MEN 2 epi On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox MEN 2 epi

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox MEN 2 epi

CDC on Sandbox MEN 2 epi

Sandbox MEN 2 epi in the news

Blogs on Sandbox MEN 2 epi

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Sandbox MEN 2 epi

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Prevalence

    • Worldwide, the prevalence of multiple endocrine neoplasia type 2 is 2.5 per 100,000 persons in 2010.
    • In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person.
    • MEN2 has been reported in approximately 500 to 1000 families worldwide.[1]
    • 70-80% of all multiple endocrine neoplasia type 2 cases are MEN type 2A.

Incidence

    • In developed countries, the incidence of (insert disease state here) is _____ per 100,000 persons.

Age

  • It can be found in all ages.
  • MEN 2B manifest in early infancy while MEN 2A and familial medullary thyroid carcinoma is found in adulthood.

Gender

  • The prevalence and incidence of multiple endocrine neoplasia type 2 does not vary by gender.

Race

  • The prevalence of multiple endocrine neoplasia type 2 does not vary by race.

Developed Countries

  • In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person..

References

  1. ↑ "Orphanet".
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_MEN_2_epi&oldid=1160185"